Journal article
Pituitary adenylate cyclase-activating polypeptide signalling as a therapeutic target in migraine
Nature reviews. Neurology, Vol.20(11), pp.660-670
11/2024
DOI: 10.1038/s41582-024-01011-4
PMID: 39256637
Abstract
Migraine is a disabling neurological disorder that affects more than one billion people worldwide. The clinical presentation is characterized by recurrent headache attacks, which are often accompanied by photophobia, phonophobia, nausea and vomiting. Although the pathogenesis of migraine remains incompletely understood, mounting evidence suggests that specific signalling molecules are involved in the initiation and modulation of migraine attacks. These signalling molecules include pituitary adenylate cyclase-activating polypeptide (PACAP), a vasoactive peptide that is known to induce migraine attacks when administered by intravenous infusion to people with migraine. Discoveries linking PACAP to migraine pathogenesis have led to the development of drugs that target PACAP signalling, and a phase II trial has provided evidence that a monoclonal antibody against PACAP is effective for migraine prevention. In this Review, we explore the molecular and cellular mechanisms of PACAP signalling, shedding light on its role in the trigeminovascular system and migraine pathogenesis. We then discuss emerging therapeutic strategies that target PACAP signalling for the treatment of migraine and consider the research needed to translate the current knowledge into a treatment for migraine in the clinic.
Details
- Title: Subtitle
- Pituitary adenylate cyclase-activating polypeptide signalling as a therapeutic target in migraine
- Creators
- Håkan Ashina - Copenhagen University HospitalRune H. Christensen - Copenhagen University HospitalDebbie L. Hay - University of OtagoAmynah A. Pradhan - Washington University in St. LouisJan Hoffmann - King's College LondonDora Reglodi - University of PecsAndrew F. Russo - University of IowaMessoud Ashina - Copenhagen University Hospital
- Resource Type
- Journal article
- Publication Details
- Nature reviews. Neurology, Vol.20(11), pp.660-670
- DOI
- 10.1038/s41582-024-01011-4
- PMID
- 39256637
- NLM abbreviation
- Nat Rev Neurol
- ISSN
- 1759-4758
- eISSN
- 1759-4766
- Publisher
- NATURE PORTFOLIO
- Language
- English
- Electronic publication date
- 09/10/2024
- Date published
- 11/2024
- Academic Unit
- Neurology; Molecular Physiology and Biophysics; Iowa Neuroscience Institute; Craniofacial Anomalies Research Center
- Record Identifier
- 9984702835102771
Metrics
7 Record Views